NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis $1.32 -0.01 (-0.75%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MAIA Biotechnology alerts:Sign Up Key Stats Today's Range$1.30▼$1.3550-Day Range$1.20▼$1.4852-Week Range$0.87▼$3.19Volume243,184 shsAverage Volume373,169 shsMarket Capitalization$80.30 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MAIA Biotechnology, Inc. is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications. The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions. Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.AI Generated. May Contain Errors. Read More MAIA Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreMAIA MarketRank™: MAIA Biotechnology scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MAIA Biotechnology. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MAIA Biotechnology are expected to grow in the coming year, from ($0.54) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MAIA Biotechnology is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MAIA Biotechnology is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMAIA Biotechnology has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MAIA Biotechnology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.64% of the float of MAIA Biotechnology has been sold short.Short Interest Ratio / Days to CoverMAIA Biotechnology has a short interest ratio ("days to cover") of 8.09.Change versus previous monthShort interest in MAIA Biotechnology has recently decreased by 10.30%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMAIA Biotechnology does not currently pay a dividend.Dividend GrowthMAIA Biotechnology does not have a long track record of dividend growth. News and Social Media4.6 / 5News Sentiment1.40 News SentimentMAIA Biotechnology has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for MAIA Biotechnology this week, compared to 2 articles on an average week.Search Interest2 people have searched for MAIA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $202,791.00 in company stock, which represents 0.2526% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, MAIA Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $202,791.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.81% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.65% of the stock of MAIA Biotechnology is held by institutions.Read more about MAIA Biotechnology's insider trading history. Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAIA Stock News HeadlinesMAIA Biotechnology Inc.September 2 at 7:45 PM | barrons.comMAIA Biotechnology (NYSEAMERICAN:MAIA) Director Ramiro Guerrero Purchases 8,931 SharesSeptember 2 at 5:52 AM | insidertrades.comLabor Day Warning: The secret that called 1929 is flashing something newIn 1929, a young researcher named Irving Weiss spotted warning signs Wall Street ignored - then watched the Dow crash nearly 13% in a single day, followed by another 12% drop the next. His research became Weiss Ratings, a system The Wall Street Journal ranked number one for investment performance. It also called the Dot-Com Bust, the 2008 crisis, and the 2020 crash. Now the system is flagging a possible shift in the back half of 2026, separating stocks it flags as vulnerable from those positioned to climb.September 4 at 1:00 AM | Weiss Ratings (Ad)MAIA BIOTECHNOLOGY INCAugust 28, 2026 | finanznachrichten.deRamiro Guerrero Acquires 11,899 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) StockAugust 25, 2026 | insidertrades.comDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)August 17, 2026 | globenewswire.comNoble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA)July 10, 2026 | theglobeandmail.comMAIA reports positive efficacy results from Phase II trial for NSCLCJuly 9, 2026 | yahoo.comSee More Headlines MAIA Stock Analysis - Frequently Asked Questions How have MAIA shares performed this year? MAIA Biotechnology's stock was trading at $1.53 at the beginning of the year. Since then, MAIA shares have decreased by 13.7% and is now trading at $1.32. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.02. Who are MAIA Biotechnology's major shareholders? MAIA Biotechnology's top institutional shareholders include Solas Capital Management LLC (4.98%), Centric Wealth Management (1.31%), Cable Car Capital LP (0.85%) and BlackRock Inc. (0.66%). Insiders that own company stock include Stan Smith, Ngar Yee Louie, Vlad Vitoc, Ramiro Guerrero, Cristian Luput and Sergei Gryaznov. View institutional ownership trends. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MAIA Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that MAIA Biotechnology investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL), Adobe (ADBE) and AppLovin (APP). Company Calendar Last Earnings8/10/2026Today9/04/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MAIA's financial health is in the Yellow zone, according to TradeSmith. MAIA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:MAIA CIK1878313 Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-211.15% Return on Assets-126.26% Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book3.88Miscellaneous Outstanding Shares60,830,000Free Float48,783,000Market Cap$80.30 million OptionableNot Optionable Beta0.25 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSEAMERICAN:MAIA) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersTrump’s “new Petrodollar” exposedTrump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...Porter & Company | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | SponsoredMan Who Called SpaceX Rise Says Elon’s NEW Project is Even BiggerJames Altucher called the rise of Nvidia, Apple, and SpaceX years before the crowd. Now he says he has uncover...Paradigm Press | SponsoredHalf the market is standing on a trapdoorNearly half the value of the US stock market now sits in AI stocks - the most concentrated the market has been...Behind the Markets | SponsoredWall Street pays $32K for this type of stock market data. (But see this Labor Day deal now!)The Bloomberg Terminal costs $32,000 a year and sits on the desks of more than 350,000 Wall Street traders. Mo...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MAIA Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MAIA Stock Alerts